文献速递肾血管病与高血压慢性肾脏病

血清钾短期变化与后续血管事件及死亡风险:ACE抑制剂随机对照试验结果

Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality: Results from a Randomized Controlled Trial of ACE Inhibitors.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-07-27

基于ADVANCE试验,2型糖尿病血糖正常者在导入期启动ACE抑制剂固定复方治疗后3周复查血钾,9694例分为高钾血症、血糖正常和低钾血症组,随后随机继续治疗或安慰剂,中位随访4.4年。继续ACE抑制剂治疗较安慰剂显著降低主要复合终点风险(38.1 vs 42.0/1000人年,HR 0.91,95%CI 0.83-1.00,P=0.04),且不受导入期血钾短期变化影响。

要点

  • 导入期556例(6%)发生高钾血症(血钾≥5.0 mEq/L)。
  • 继续ACE抑制剂较安慰剂降低主要复合终点风险,HR 0.91(95%CI 0.83-1.00,P=0.04)。
  • 疗效在各血钾变化亚组间无显著异质性(P for heterogeneity=0.66)。

核心结论

  • 无论血清钾短期如何变化,继续ACE抑制剂为基础的治疗均一致降低后续临床结局风险,包括心血管和肾脏结局及死亡。

研究设计与样本

  • 数据来自ADVANCE试验,导入期所有参与者启动ACE抑制剂为基础的治疗(培哚普利和吲达帕胺固定复方)。
  • 研究人群为导入期开始时血钾正常(3.5至<5.0 mEq/L)的2型糖尿病患者。
  • 3周后复查血钾,9694例参与者分为高钾血症(≥5.0 mEq/L)、血糖正常和低钾血症(<3.5 mEq/L)组,随后随机继续ACE抑制剂治疗或安慰剂,中位随访4.4年。

主要发现

  • 导入期556例(6%)参与者发生高钾血症。
  • 随访期间1505例参与者发生主要大血管和微血管事件复合终点。
  • 继续ACE抑制剂为基础的治疗较安慰剂显著降低主要终点风险(38.1 vs 42.0/1000人年;HR 0.91;95%CI 0.83-1.00;P=0.04)。
  • 疗效在各导入期血钾短期变化亚组间无显著差异(异质性P=0.66)。
  • 全因死亡、心血管死亡、主要冠脉事件、主要脑血管事件及新发或恶化肾病也观察到一致的治疗效应(异质性P≥0.27)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Hyperkalemia after starting renin-angiotensin system inhibitors has been shown to be subsequently associated with a higher risk of cardiovascular and kidney outcomes. However, whether to continue or discontinue the drug after hyperkalemia remains unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data came from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, which included a run-in period where all participants initiated angiotensin-converting enzyme inhibitor-based therapy (a fixed combination of perindopril and indapamide). The study population was taken as patients with type 2 diabetes with normokalemia (serum potassium of 3.5 to <5.0 mEq/L) at the start of run-in. Potassium was remeasured 3 weeks later when a total of 9694 participants were classified into hyperkalemia (≥5.0 mEq/L), normokalemia, and hypokalemia (<3.5 mEq/L) groups. After run-in, patients were randomized to continuation of the angiotensin-converting enzyme inhibitor-based therapy or placebo; major macrovascular, microvascular, and mortality outcomes were analyzed using Cox regression during the following 4.4 years (median). RESULTS: During active run-in, 556 (6%) participants experienced hyperkalemia. During follow-up, 1505 participants experienced the primary composite outcome of major macrovascular and microvascular events. Randomized treatment of angiotensin-converting enzyme inhibitor-based therapy significantly decreased the risk of the primary outcome (38.1 versus 42.0 per 1000 person-years; hazard ratio, 0.91; 95% confidence interval, 0.83 to 1.00; P=0.04) compared with placebo. The magnitude of effects did not differ across subgroups defined by short-term changes in serum potassium during run-in (P for heterogeneity =0.66). Similar consistent treatment effects were also observed for all-cause death, cardiovascular death, major coronary events, major cerebrovascular events, and new or worsening nephropathy (P for heterogeneity ≥0.27). CONCLUSIONS: Continuation of angiotensin-converting enzyme inhibitor-based therapy consistently decreased the subsequent risk of clinical outcomes, including cardiovascular and kidney outcomes and death, regardless of short-term changes in serum potassium. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE), NCT00145925.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Ohkuma T, Harris K, Cooper M, et al. Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality: Results from a Randomized Controlled Trial of ACE Inhibitors. Clin J Am Soc Nephrol. 2022. PMID: 35896277. doi:10.2215/CJN.00180122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。